Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-24
    E.g., 2018-09-24

Articles

19391 items
3:58 PM, Sep 14, 2018  |  BioCentury | Regulation

Closing NICE’s Orphan gap

As the list of Orphan drugs rejected by NICE grows, industry and patient groups are pressuring the agency to make broader use of tools that currently apply only to selected ultra-Orphan therapies. These tools allow...
2:51 PM, Sep 14, 2018  |  BioCentury | Finance

Coda’s chemogenetic control

Coda Biotherapeutics Inc. could have first-mover potential in the chemogenetics space, and with a newly raised $19 million series A round, the company will move its first program toward the clinic. Seed investors MPM Capital...
12:44 PM, Sep 14, 2018  |  BioCentury | Emerging Company Profile

Laekna’s jumping off place

Chinese biotech Laekna Therapeutics Shanghai Co. Ltd. is jump-starting its pipeline with a trio of clinical cancer compounds from Novartis AG. The safety of the lead candidate and its potential to synergize with the other...
12:18 PM, Sep 14, 2018  |  BioCentury | Finance

Zai shores up

As Zai Lab Ltd. (NASDAQ:ZLAB) prepares for its first product launch, more clinical work and additional deals to fortify its pipeline, the company passed on the chance to list on Hong Kong’s new biotech chapter,...
5:00 PM, Sep 07, 2018  |  BioCentury | Product Development

Data distribution

TransCelerate BioPharma Inc. is taking its data sharing initiative to the next level with a new platform that will integrate clinical and preclinical data sets in a single repository and provide new analytical tools. DataCelerate,...
1:17 PM, Sep 07, 2018  |  BioCentury | Strategy

Thinking beyond Bi

Following the resignation of Jingquan Bi, early signs for continued biopharma regulatory reform in China remain positive. But the IP reforms spearheaded by Bi look to have fallen off the government’s priority list, and there...
11:46 AM, Sep 07, 2018  |  BioCentury | Emerging Company Profile

Leveraging cross-linking

Lyvgen Biopharma Co. Ltd. is using its xLinkAb platform to develop mAbs that agonize T cell or dendritic cell co-stimulatory receptors with better safety and selectivity for tumors than competing mAbs. According to founder and CEO...
4:58 PM, Sep 06, 2018  |  BioCentury | Finance

Jacobio’s ladder

Beijing Jacobio Pharmaceutical Co. Ltd. plans to use its $55 million series C round to fuel its creation of spinouts housing internally developed assets. Existing investor Qiming Venture Partners led the tranched round, which closed on...
4:30 PM, Sep 06, 2018  |  BioCentury | Finance

Evox populates its pipeline

As Evox Therapeutics Ltd. continues to refine the platform with which it develops exosome-based therapeutics, the company plans to use its £35.5 million ($45.9 million) series B round to start clinical trials on as many...
4:04 AM, Sep 05, 2018  |  BioCentury | Finance

Fulcrum’s genetic levers

Fulcrum Therapeutics Inc.’s ability to identify targets for genetic disease drivers using bioinformatics prompted Foresite Capital to lead the company’s untranched $80 million series B round. Fellow new investors Fidelity, 6 Dimensions Capital, Casdin Capital,...

Pages